Financial Performance - The company reported a net profit attributable to ordinary shareholders of approximately CNY 419.41 million for the first half of 2023, with a basic earnings per share of CNY 0.37 and diluted earnings per share of CNY 0.33[7]. - The company recognized non-recurring gains of CNY 122.54 million, with a net profit after deducting these gains amounting to CNY 296.87 million[7]. - Total net profit after deducting non-recurring gains and losses for the reporting period (January to June) was approximately CNY 296.87 million, an increase of 57.58% compared to the same period last year[22]. - The company’s net profit for the first half of 2023 reached CNY 431,107,180.61, an increase of 35% compared to CNY 319,368,051.58 in the same period of 2022[50]. - Operating profit for the first half of 2023 was CNY 550,256,415.27, up from CNY 410,422,340.19 in the previous year, reflecting a growth of approximately 34%[50]. - The company reported a total profit of CNY 503,502,808.33 for the first half of 2023, compared to CNY 407,961,490.93 in the previous year, marking a growth of approximately 23%[50]. - Total operating revenue for the first half of 2023 reached ¥6,060,103,056.03, an increase of 5.65% compared to ¥5,736,689,223.53 in the same period of 2022[38]. - Total operating costs amounted to ¥5,564,001,745.74, up from ¥5,402,764,290.71, reflecting a rise of 2.98%[38]. Research and Development - Research and development expenses totaled CNY 101.17 million in the current period, an increase from CNY 89.76 million in the previous period, reflecting a growth of approximately 12.9%[2]. - The company incurred a total of CNY 30.68 million in employee compensation as part of its R&D expenses, up from CNY 26.45 million in the previous period[2]. - Research and development expenses increased to ¥210,712,020.46, compared to ¥181,439,748.83, marking a growth of 16.14%[38]. - The company continues to focus on innovation and compliance as key drivers for growth in the pharmaceutical sector[45]. Shareholder Information - The number of shareholders at the end of the reporting period was 29,338,100, with a decrease of 1,244,000 during the reporting period[1]. - The top shareholder, Zhejiang Haizheng Group Co., Ltd., held 320,783,590 shares, representing 26.52% of total shares[1]. - The second-largest shareholder, Zhejiang Provincial International Trade Group Co., Ltd., reduced its holdings by 1,974,000 shares, holding 72,673,907 shares or 6.01%[1]. Assets and Liabilities - The company’s total net assets attributable to ordinary shareholders at the beginning of the period were CNY 8.08 billion[7]. - The company’s total liabilities were 9.442 billion yuan, down from 10.454 billion yuan at the end of the previous year[36]. - The company’s total equity attributable to shareholders was 8.629 billion yuan, an increase from 8.079 billion yuan at the end of the previous year[36]. - The company’s total assets were 18.334 billion yuan, down from 18.785 billion yuan at the end of the previous year[36]. - As of the end of the reporting period, the company's current liabilities amounted to 6.737 billion yuan, a decrease of 396 million yuan or 5.56% compared to the beginning of the year, primarily due to the repayment of short-term financing[30]. - The company's non-current liabilities totaled 2.705 billion yuan, a decrease of 616 million yuan or 18.55% compared to the beginning of the year, mainly due to the conversion of convertible bonds and long-term loans maturing within one year[30]. Cash Flow and Dividends - Cash flow from operating activities generated a net amount of CNY 741,725,087.61, a decrease of 29% from CNY 1,048,070,078.82 in the first half of 2022[53]. - The company paid CNY 256,135,891.20 in dividends during the first half of 2023, compared to CNY 226,256,436.29 in the same period of 2022, reflecting an increase of about 13%[57]. Financial Ratios - The weighted average return on net assets was reported at 5.08% for the first half of 2023[8]. - The debt-to-asset ratio decreased by 4.15 percentage points to 51.50% compared to the previous year[22]. - The interest coverage ratio improved to 5.24, up 53.67% from 3.41 in the same period last year[22]. - The cash interest coverage ratio was 10.14, showing a slight increase of 3.79% compared to 9.77 last year[22]. - The company’s EBITDA to total debt ratio improved to 0.18, an increase of 38.46% from 0.13 in the same period last year[22]. Inventory and Receivables - The company's inventory stood at 613 million yuan, slightly down from 616 million yuan at the end of the previous year[36]. - The company's accounts receivable balance at the end of the period is CNY 2,835,448,956.41, with CNY 2,779,007,528.43 being within one year[166]. - The total amount of inventory is 1,347,911,571.35 RMB, with a provision for inventory depreciation of 113,404,146.82 RMB[193]. - The company has recognized a total of CNY 2,826,621,805.68 in accounts receivable, with varying provision rates for different aging categories[173]. Investments - The total balance of investments in joint ventures and associates at the end of the period was approximately 1.13 billion for Yasal and 2.18 billion for Zhejiang Xinyi Ruijue Pharmaceutical Co., Ltd.[200]. - The company holds a 40.32% stake in Zhejiang Borui Biopharmaceutical Co., Ltd. and a 49.00% stake in Yasalili (Taizhou) Pharmaceutical Co., Ltd., both accounted for using the equity method[92]. - The investment in Zhejiang Borui Biopharmaceutical Co., Ltd. showed a balance of approximately 1.14 billion, with a loss recognized under the equity method of approximately 13.18 million[200]. Risk Management - The company has detailed potential risks in its report, specifically in the section "Management Discussion and Analysis" under "Risks Faced"[94]. - The company’s financial instruments are assessed for expected credit losses based on historical experience and current economic conditions[108]. - The expected credit loss rates for accounts receivable are set at 5.00% for within one year, 10.00% for 1-2 years, and 30.00% for 2-3 years[110].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）第九届董事会第十七次 会议于 2023 年 8 月 18 日（周五）下午以通讯方式召开，应参加本次会议董事 8 人，亲自参加会议董事 8 人。本次会议的召开程序符合《公司法》和《公司章程》 的规定，会议合法有效。本次会议由公司董事长蒋国平先生主持，经审议，与会 董事以通讯表决方式通过以下决议： 股票简称：海正药业 股票代码：600267 公告编号：临 2023-85 号 债券简称：海正定转 债券代码：110813 浙江海正药业股份有限公司 第九届董事会第十七次会议决议公告 一、2023 年半年度报告及摘要； 同意 8 票，反对 0 票，弃权 0 票。 2023 年半年度报告全文及摘要详见上海证券交易所网站（www.sse.com.cn）， 2023 年半年度报告摘要同时登载于 2023 年 8 月 22 日的《中国证券报》《上海证 券报》《证券时报》。 二、关于公司变更注册资本并修订《公司章程》及办理工商变更登记的议 案； 同意 8 票 ...

浙江海正药业股份有限公司章程 浙江海正药业股份有限公司 章 程 二○二三年八月 第 1 页 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 2 | | 第三章 | 股份 | 2 | | 第一节 | 股份发行 | 2 | | 第二节 | 股份增减和回购 | 3 | | 第三节 | 股份转让 | 4 | | 第四章 | 股东和股东大会 | 5 | | 第一节 | 股东 | 5 | | 第二节 | 股东大会的一般规定 | 7 | | 第三节 | 股东大会的召集 | 9 | | 第四节 | 股东大会的提案与通知 | 10 | | 第五节 | 股东大会的召开 | 11 | | 第六节 | 股东大会的表决和决议 | 14 | | 第五章 | 董事会 | 18 | | 第一节 | 董事 | 18 | | 第二节 | 独立董事 | 20 | | 第三节 | 董事会 | 21 | | 第四节 | 董事会秘书 | 25 | | 第六章 | 经理及其他高级管理人员 | 27 | | 第七章 | 监事会 | 28 | | 第一节 | 监事 | 28 | | 第二节 | 监 ...

| 证券代码：600267 | 证券简称：海正药业 | 公告编号：2023-88 号 | | --- | --- | --- | | 债券代码：110813 | 债券简称：海正定转 | | 浙江海正药业股份有限公司关于持股 5%以上股东集 中竞价减持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，浙江海正药业股份有限公司（以下简称"公司"）持 股 5%以上股东浙江省国际贸易集团有限公司（以下简称"国贸集团"）持有公司 无限售条件流通股 74,647,907 股，占当时公司总股本的 6.32%。 由于首次及预留授予激励对象 29 人不再具备股权激励资格及 1 人因个人业 绩考核要求未达标，公司于 2023 年 7 月 6 日办理完毕上述激励对象持有的全部 或部分限制性股票共计 1,639,400 股的回购注销手续；另因公司可转换公司债券 发生转股，截至本公告披露日，累计转股股数为 29,122,774 股。由于公司总股本 发生变动，国贸集团在本次减持 ...

| 股票简称：海正药业 | 股票代码：600267 公告编号：临2023-86号 | | --- | --- | | 债券简称：海正定转 | 债券代码：110813 | 浙江海正药业股份有限公司 关于变更注册资本并修订《公司章程》的公告 1 元，减少资本公积（股本溢价）人民币12,723,070.47元。截至2023年7月6日， 公司变更后的注册资本为人民币1,207,873,677.00元，实收资本为人民币 1,207,873,677.00元。 上述可转债转股及限制性股票回购注销手续完成后，公司总股本将增加至 1,207,873,677股，公司注册资本将增加至120,787.3677万元。根据《中华人民共 和国公司法》及《公司章程》相关规定，鉴于公司注册资本和股份总数发生变 化，公司对《公司章程》部分条款进行相应修订，具体内容如下： | 修订前 | | 修订后 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 第六条 公 司 注 册 资 本 为 人 民 币 | | 第六条 | | | | 公 司 注 册 资 本 为 人 民 币 | | 118,0 ...

| 证券代码：600267 | 证券简称：海正药业 | 公告编号：临 | 2023-87 | 号 | | --- | --- | --- | --- | --- | | 债券代码：110813 | 债券简称：海正定转 | | | | 浙江海正药业股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第一次临时股东大会 召开的日期时间：2023 年 9 月 19 日 13 点 30 分 召开地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙路 46 号） (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 19 日 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 ...

浙江海正药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 | 证券简称：海正药业 | 证券代码：600267 | 公告编号：2023-84 | 号 | | --- | --- | --- | --- | | 债券简称：海正定转 | 债券代码：110813 | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 15 日（星期二）至 8 月 21 日（星期一）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过浙江海正药业股份有限 公司（以下简称"公司"）证券管理部邮箱 stock600267@hisunpharm.com 进行提 问。公司将在信息披露允许的范围内，于说明会上对投资者普遍关注的问题进行 回答。 公司将于 2023 年 8 月 22 日发布公司 2023 年半年度报告，为便于广大投资 者更全面深入地了解公司 2023 年半年度经 ...

| 证券简称：海正药业 | 证券代码：600267 | 公告编号：2023-48 | 号 | | --- | --- | --- | --- | | 债券简称：海正定转 | 债券代码：110813 | | | 浙江海正药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 12 日（星期五）至 5 月 18 日（星期四）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司证券管理部邮箱 stock600267@hisunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 浙江海正药业股份有限公司（以下简称"公司"）已分别于 2023 年 3 月 31 日、4 月 25 日发布公司 2022 年年度报告、2023 年第一季度报告，为便于广大投 资者更全 ...

Financial Performance - In Q1 2023, the company's operating revenue reached CNY 3,063,534,009.22, representing a year-on-year increase of 2.90%[9] - The net profit attributable to shareholders was CNY 232,298,844.11, reflecting a significant increase of 71.91% compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 169,061,721.09, up by 48.72% year-on-year[9] - Basic earnings per share increased by 72.73% to CNY 0.19, while diluted earnings per share rose by 54.55% to CNY 0.17[9] - Comprehensive income for Q1 2023 totaled ¥240,143,329.60, compared to ¥136,134,173.84 in Q1 2022, reflecting strong growth[22] - The net profit for the first quarter of 2023 was CNY 241,532,224.51, an increase from CNY 135,971,298.82 in the same period last year, representing a growth of approximately 77.6%[42] - Operating profit for the first quarter was CNY 295,762,745.82, compared to CNY 181,607,982.50 in the previous year, indicating an increase of approximately 62.8%[42] - The total profit before tax was CNY 295,646,621.49, up from CNY 183,816,282.58, marking an increase of around 60.6%[42] Cash Flow and Investments - The net cash flow from operating activities was CNY 304,464,171.32, showing a growth of 6.24% year-on-year[9] - The net cash flow from operating activities for Q1 2023 was RMB 304,464,171.32, an increase of 6.2% compared to RMB 286,573,768.25 in Q1 2022[24] - Cash inflow from investment activities totaled RMB 31,517,134.88, up from RMB 29,917,951.01 in Q1 2022[25] - The net cash flow from financing activities was RMB 47,584,427.73, a decrease of 75.6% compared to RMB 194,941,690.12 in Q1 2022[25] - The company’s net cash flow from investment activities was negative at RMB -130,004,909.59, an improvement from RMB -241,899,741.78 in Q1 2022[25] Assets and Liabilities - The total current assets as of March 31, 2023, amounted to CNY 6,742,231,451.07, an increase from CNY 6,409,130,185.76 at the end of 2022[17] - Total assets as of the end of the reporting period were ¥18,837,252,014.87, compared to ¥18,777,887,149.36 at the end of the previous period[20] - Total liabilities decreased to ¥10,259,396,669.44 from ¥10,447,695,366.55 in the previous period[20] - The equity attributable to shareholders of the listed company increased by 2.95% to RMB 8,317,395,017.99 from RMB 8,079,089,182.11 at the end of the previous year[30] Research and Development - The company continues to invest in R&D, with development expenditures reported at ¥184,430,988.46, slightly up from ¥183,719,221.12 in the previous period[20] - Research and development expenses increased to CNY 97,041,933.90 from CNY 83,286,810.37, reflecting a rise of about 16.5% year-over-year[42] Shareholder Information - The company maintained a strong shareholder base, with the largest shareholder, Zhejiang Haizheng Group Co., Ltd., holding 27.18% of the shares[49] Other Financial Metrics - The company reported a significant increase in interest income, rising to CNY 5,009,916.05 from CNY 3,601,456.79, which is an increase of approximately 38.9%[42] - The company’s tax expenses for the quarter were CNY 54,114,396.98, compared to CNY 47,844,983.76 in the previous year, reflecting an increase of about 13.4%[42] - The company’s financial expenses decreased to CNY 55,893,826.52 from CNY 74,422,505.49, a reduction of approximately 25%[42] - The investment income showed a recovery, with a profit of CNY 7,610,239.93 compared to a loss of CNY 7,286,525.19 in the previous year[42]